Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 1PC111
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 1PC111 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 24, 2020
Lead Product(s) : 1PC111
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Durect
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oradur (Methylphenidate) is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Oradur
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 10, 2016
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Durect
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : National Defense Medical Center, Taiwan | NRPB, Taiwan
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis
Details : Isoniazid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Tuberculosis, Pulmonary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 10, 2015
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : National Defense Medical Center, Taiwan | NRPB, Taiwan
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Durect
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
Details : Methylphenidate is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 21, 2015
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Durect
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 1PC002
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Europharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia
Details : 1PC002 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 18, 2012
Lead Product(s) : 1PC002
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Europharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxybutynin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oxybutynin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sialorrhea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 10, 2011
Lead Product(s) : Oxybutynin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
